MIT Sloan alumnus preps milestone spinal injury study

Frank Reynolds, SF ’06, explains his company’s groundbreaking new technology

May 23, 2013

Frank Reynolds, SF '06Frank Reynolds, SF ’06

Just off campus, an MIT Sloan graduate’s medical device company is preparing the first human trial of a device to treat spinal cord injuries.

InVivo Therapeutics is developing a “scaffold” intended to halt the inflammation of spinal tissue following an injury, its CEO, Frank Reynolds, SF ’06, told Boston NPR station WBUR this week. Five patients, paralyzed for only a few days or weeks, will participate in the study.

Reynolds, who was paralyzed for eight days in 1992 following surgery, told WBUR that the goal is for the company’s device to halt scarring in the spinal tissue. By giving surviving cells “something to cling to,” Reynolds says the cells could begin to grow again, allowing patients to regain some function.

Reynolds co-founded InVivo in 2005 after he met MIT biomedical engineer Robert Langer while studying in the MIT Sloan Fellows Program in Innovation and Global Leadership, a full-time, 12-month MBA or Master of Science designed for mid-career professionals.

At MIT Sloan, Reynolds developed InVivo in his New Enterprises class and was a finalist in the MIT $100K Entrepreneurship Competition. The company today is located in Kendall Square in Cambridge.